Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Erythrocyte membrane protein band 4.2 (EPB42) is a peripheral membrane ATP-binding protein that is one of the most abundant components of the human red blood cell (erythrocyte) membrane[1][4][5]. It plays an essential role in stabilizing erythrocyte membrane structure, primarily by regulating the association between the band 3 protein and ankyrin, and is part of the ankyrin-1 complex[1][4][5]. Through its physical association with band 3, ankyrin, and CD47, protein 4.2 helps maintain the distinctive shape and mechanical properties of erythrocytes[4]. Deficiencies or mutations in EPB42 cause disorders such as hereditary spherocytosis and elliptocytosis, characterized by destabilization of the erythrocyte membrane and hemolytic anemia[1][4][5]. Protein 4.2 is structurally similar to members of the transglutaminase protein family, although it lacks transglutaminase enzymatic activity[2][4]. There is currently no evidence that it is a direct therapeutic target or that any drugs interact with it[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Erythrocyte membrane protein band 4.2 (EPB42).